

February 10th, 2026

Acuitas Therapeutics Named One of BC's Top Employers

Vancouver, B.C. – Acuitas Therapeutics, the global leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, has been named one of BC's Top Employers in 2026 for the third year in a row. A recipient of the Canada's Top Small & Medium Employers (2025) and Canada's Most Admired™ Corporate Cultures (2024), this award highlights Acuitas' continued commitment in creating a workplace culture that empowers innovation, fosters inclusivity, and supports the personal and professional growth of every team member.

"We are honoured to be named one of BC's Top Employers for the third consecutive year," said CEO, Dr. Thomas Madden. He added: "Acuitas is built on a culture that values scientific excellence, collaboration, and inclusion. Our success comes from fostering an environment where our team members can do their best work and this is reflected in the scientific and clinical advances we are making at Acuitas and with our partners. This recognition reflects the value of that culture."

Read the full list of BC's Top Employers [here](#).

About Acuitas Therapeutics

Acuitas Therapeutics Inc., the global leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, is a Vancouver-based company collaborating with pharmaceutical and biotech companies, academic researchers, and global health organizations to advance a broad range of medicines for a variety of diseases.

Acuitas' clinically validated LNP technology has had a profound global impact — most notably enabling the Pfizer-BioNTech COVID-19 vaccine, **COMIRNATY®**, which has protected billions of people in more than 180 countries. Its technology also enables **ONPATTRO®** by Alnylam Pharmaceuticals, the first FDA-approved RNAi therapeutic for treating the rare and fatal disease transthyretin amyloidosis. More recently, Acuitas' LNP technology has delivered other groundbreaking firsts: the **first in-human proof of concept** for genome base editing and the **first personalized CRISPR therapy**.

Today, Acuitas is advancing next-generation LNP to support a variety of therapeutic modalities. This includes targeted LNP for extrahepatic and in vivo CAR T-cell therapies, epigenetic medicines to modulate gene expression without altering DNA, and multivalent vaccines for



infectious diseases — such as malaria, HIV/AIDS, and tuberculosis — as well as oncology vaccines, including personalized cancer vaccines.

For more information, please visit www.AcuitasTx.com.

-END-